ARLINGTON, Va. – National Association of Chain Drug Stores (NACDS) president and CEO Steven Anderson issued the following statement Tuesday:
“Words like ‘continuing resolution,’ ‘budget reconciliation,’ and ‘standalone bill’ are the words of Washington, DC. While all of these legislative vehicles are sorted out, one fact remains: pharmacy benefit manager (PBM) reform remains a long overdue need and the costs of inaction continue to ravage Americans, their pharmacies, and their communities.
“Every day, Americans are living with the acceleration of prescription drug price inflation and the closing of trusted and convenient pharmacies.At the hands of the PBM middlemen, nearly four pharmacies are closing each day – at an increasing rate. Americans have missed out on hundreds of millions of dollars of savings just since the last Congress ended. The costs of inaction on PBM reform are massive and they are growing, all while the PBMs redouble their revenue.
"Meanwhile, Congress has reforms ready to go – a sound package that was finalized last December. Americans need this win and it is time to deliver it to them. As Congress and the Administration figure out the legislative roadmap, PBM reform needs to get done without further needless delay.”
More information is available on a new NACDS fact sheet.
NACDS: A legislative vehicle must include PBM reform; inaction is costing Americans
Nearly four pharmacies are closing every day; Americans are missing out on hundreds of millions in savings just since the last Congress' end.
Related
Senate finance leaders introduce bipartisan PBM Reform, NACDS hails move and calls for swift passage
Legislation aims to curtail harmful PBM middlemen tactics that inflate drug costs and force pharmacies to close.
NCPA urges Congress to pass Crapo-Wyden PBM Reforms
Wide bipartisan support means no more excuses, says NCPA.
CVS Health to pay $37.76 million over insulin pen overbilling allegations
Settlement resolves decade-long False Claims Act violations tied to premature refills and inaccurate reporting to federal health care programs.
Camber launches Imatinib Mesylate Tablets
Imatinib is an oral targeted therapy used for several cancers and other conditions caused by specific genetic mutations.
Latest
Circana: Fragrance demand expected to rise this holiday season
About one in five consumers purchased fragrance as a holiday gift last year, and purchase intentions are even higher this year.
Americans’ grocery carts score far below health benchmark
The FoodHealth Score assesses purchases based on nutrient density and ingredient quality.
Brian Wynne named chair of American Heart Association's 2026 First Coast Heart Ball
Heart Ball chairmanship centers on advocacy, access, and care for military families.
Facts up Front, SmartLabel gain recognition as transparency efforts grow
According to research from the Consumer Brands Association, 90% of Americans recognize Facts Up Front, and 22 million SmartLabel scans occur each year.